We are conducting two parallel drug development programs that are exploring the potential of MOSPD2, a protein which we identified as a key regulator of cell motility, as a therapeutic target for inflammatory diseases and cancer.

MOSPD2 is a membrane protein whose function was unknown. We discovered new biology findings in the regulation of cell motility, in which MOSPD2 seems to be playing a key role.  Our data indicate that MOSPD2 is required for directional movement, or chemotaxis, of tumor cells and certain immune cells.

Our VB-600 platform of biologic agents is targeting MOSPD2 for oncology and inflammatory indications.